STOCK TITAN
  1. Home
  2. Sec-filings
  3. SXTP
  4. [8-K] 60 DEGREES PHARMACEUTICALS, INC. Reports Material Event

60 Degrees Pharmaceuticals (NASDAQ: SXTP) reports 2026 shareholder vote outcomes

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

60 Degrees Pharmaceuticals, Inc. held its virtual 2026 annual stockholders meeting on August 5, 2026. As of the July 2, 2026 record date, 2,659,288 shares of common stock were outstanding. Holders of 1,107,592 shares, about 41.6% of the voting shares, were represented in person or by proxy, establishing a quorum pursuant to the Delaware General Corporation Law and the company’s amended and restated bylaws.

Stockholders cast more votes “for” than “withheld” for each of the five director nominees, including Geoffrey Dow (147,223 for; 25,031 withheld) and Eric Francois (141,202 for; 31,052 withheld), with 935,338 broker non-votes on each election. For each additional proposal on the agenda, the required affirmative vote of a majority of shares represented at the meeting was achieved, and each proposal was approved, with reported “for” votes ranging from 92,303 to 997,089.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Shares outstanding 2,659,288 shares Common stock outstanding as of July 2, 2026 record date
Shares represented at meeting 1,107,592 shares Voting stock represented at the August 5, 2026 annual meeting
Quorum percentage 41.6% Portion of outstanding voting shares represented at the 2026 meeting
Votes for Geoffrey Dow 147,223 votes Director nominee "for" votes at 2026 annual meeting
Broker non-votes on director elections 935,338 votes Broker non-votes recorded for each director nominee
Highest proposal support 997,089 votes for Largest "for" vote total among non-director proposals approved
broker non-votes regulatory
"Votes For 147,223; Votes Withheld 25,031; Broker Non-Votes 935,338"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Delaware General Corporation Law regulatory
"a quorum pursuant to the Delaware General Corporation Law and the amended"
A set of state laws that acts like a rulebook for how corporations are formed, governed, and dissolved in Delaware. It lays out legal duties for company leaders, protections and voting rights for shareholders, and rules for mergers and other big transactions, giving investors clearer expectations about how corporate decisions are made and disputes are resolved—similar to having standardized traffic laws for business behavior.
amended and restated bylaws regulatory
"pursuant to the Delaware General Corporation Law and the amended and restated bylaws"
A company’s amended and restated bylaws are its internal rulebook rewritten to include all changes in one updated document, replacing the old bylaws. For investors, this matters because the bylaws set how the board, shareholders and officers make decisions, hold votes and handle disputes; a new consolidated version can change voting rights, control mechanisms or procedures that affect corporate governance and the value or risk of an investment.
emerging growth company regulatory
"Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
quorum regulatory
"representing approximately 41.6% of the outstanding voting shares, and thereby a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What did SXTP report about its 2026 annual stockholders meeting results?
60 Degrees Pharmaceuticals reported that its virtual 2026 annual meeting was held on August 5, 2026, with a quorum present. 1,107,592 shares, about 41.6% of 2,659,288 outstanding, were represented in person or by proxy, and every proposal on the agenda was approved.

How many 60 Degrees Pharmaceuticals (SXTP) shares were outstanding for the 2026 meeting?
As of the July 2, 2026 record date, 2,659,288 shares of 60 Degrees Pharmaceuticals common stock were issued and outstanding. Each share was entitled to one vote on every proposal presented at the 2026 annual stockholders meeting held on August 5, 2026.

What quorum was achieved at 60 Degrees Pharmaceuticals (SXTP)'s 2026 shareholder meeting?
The meeting reached a quorum with 1,107,592 shares of voting stock represented, about 41.6% of outstanding shares. This level satisfied quorum requirements under the Delaware General Corporation Law and the company’s amended and restated bylaws for conducting business.

How did director nominees fare in the 2026 60 Degrees Pharmaceuticals (SXTP) vote?
Each of the five director nominees received more votes "for" than "withheld." For example, Geoffrey Dow received 147,223 for and 25,031 withheld votes, while Eric Francois received 141,202 for and 31,052 withheld votes, with 935,338 broker non-votes on each election.

How were the other proposals decided at 60 Degrees Pharmaceuticals (SXTP)'s 2026 meeting?
Each proposal required approval by a majority of shares represented and entitled to vote, and each was approved. Reported "for" votes included 126,984 against 44,464, and as high as 997,089 for against 86,366, with additional proposals also meeting the majority threshold.
false 0001946563 DC 0001946563 2026-08-05 2026-08-05 0001946563 SXTP:CommonStockParValue0.0001PerShareMember 2026-08-05 2026-08-05 0001946563 SXTP:WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember 2026-08-05 2026-08-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):

August 5, 2026

 

60 DEGREES PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41719   45-2406880
(State or other jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification Number)

 

1025 Connecticut Avenue NW Suite 1000,    
Washington, D.C.   20036
(Address of registrant’s principal executive office)   (Zip code)

 

(202) 327-5422

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   SXTP   The Nasdaq Stock Market LLC
Warrants, each warrant to purchase one share of Common Stock   SXTPW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On August 5, 2026, 60 Degrees Pharmaceuticals, Inc., a Delaware corporation (the “Company”), held its virtual 2026 Annual Stockholders Meeting (the “Meeting”).

 

As of the close of business on July 2, 2026, the record date for the determination of stockholders entitled to vote at the Meeting, there were 2,659,288 shares of the Company’s common stock, par value $0.0001 per share, issued and outstanding, with each share entitled to one vote on each proposal at the Meeting. At the Meeting, the combined holders of 1,107,592 shares of the voting stock entitled to notice of and to vote at the Meeting were represented in person or by proxy, representing approximately 41.6% of the outstanding voting shares, and thereby a quorum pursuant to the Delaware General Corporation Law and the amended and restated bylaws of the Company was present for the transaction of business at the Meeting.

 

The final results for each of the matters considered at the Meeting were as follows:

 

1.To elect five (5) directors to serve until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.

 

Geoffrey Dow

 

Votes For  Votes Withheld  Broker Non-Votes
147,223  25,031  935,338

 

Eric Francois

 

Votes For  Votes Withheld  Broker Non-Votes
141,202  31,052  935,338

 

Cheryl Xu

 

Votes For  Votes Withheld  Broker Non-Votes
142,103  30,151  935,338

 

Stephen Toovey

 

Votes For  Votes Withheld  Broker Non-Votes
140,160  32,094  935,338

 

Paul Field

 

Votes For  Votes Withheld  Broker Non-Votes
141,336  30,918  935,338

 

1

 

 

The affirmative vote of the holders of a majority of the shares represented at the Meeting and entitled to vote was required for approval. The proposal was approved.

 

2.To approve an amendment to the 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan to increase the number of shares of common stock available for issuance by 800,000 shares.

 

Votes For  Votes Against  Abstentions
126,984  44,464  806

 

The affirmative vote of the holders of a majority of the shares represented at the Meeting and entitled to vote was required for approval. The proposal was approved.

 

3.Approval of an amendment to the certificate of incorporation, as corrected, of the Company, to effect a reverse stock split of the common stock at a reverse stock split ratio ranging from 1:5 to 1:10 inclusive, as determined by the Board of Directors of the Company in its sole discretion:

 

Votes For  Votes Against  Abstentions
836,390  253,388  17,814

 

The affirmative vote of the holders of a majority of the shares represented at the Meeting and entitled to vote was required for approval. The proposal was approved.

 

4.To ratify the selection by the Company’s Board of Directors of RBSM LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026

 

Votes For  Votes Against  Abstentions
997,089  86,366  24,137

 

The affirmative vote of the holders of a majority of the shares represented at the Meeting and entitled to vote was required for approval. The proposal was approved.

 

5.To approve a payment to management of a success fee of five percent (5%) of deal proceeds between a deal value of $40 million and $100 million, and six percent (6%) of deal proceeds for a deal value in excess of $100 million, in the event of a change of control, strategic transaction or sale of Arakoda, to be awarded as cash or equity to members of the management team, as determined by the Board of Directors in its sole discretion.

 

Votes For  Votes Against  Abstentions
92,303  77,865  2,086

 

The affirmative vote of the holders of a majority of the shares represented at the Meeting and entitled to vote was required for approval. The proposal was approved.

 

6.To approve adjourning the Annual Meeting, if necessary, to solicit proxies in the event there are not sufficient votes in favor of the Director Election Proposal, the 2022 Plan Amendment Proposal and the Certificate of Incorporation Amendment Proposal at the time of the Annual Meeting.

 

Votes For  Votes Against  Abstentions
896,148  157,925  53,519

 

The affirmative vote of the holders of a majority of the shares represented at the Meeting and entitled to vote was required for approval. The proposal was approved.

 

2

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  60 DEGREES PHARMACEUTICALS, INC.
     
Date: August 6, 2026 By:  /s/ Geoffrey Dow
  Name: Geoffrey Dow
  Title: Chief Executive Officer and President

 

3

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Other Documents